author-photo

X. Wang

Genentech

5

Papers

81

Citations

Citation Trend

Filter By

Papers (5) Sort By

Journal Conference Others

Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck

2016 Cancer
Show All
- Source
- Cite
- Save
Citations (23)
Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors

2015 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (37)
986ORANDOMIZED PHASE II STUDY OF MEHD7945A (MEHD) VS CETUXIMAB (CET) IN >= 2ND-LINE RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD & NECK (RMSCCHN) PROGRESSIVE ON/AFTER PLATINUM-BASED CHEMOTHERAPY (PTCT)

2014 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (18)
989PDPHASE 1B STUDY OF MEHD7945A (MEHD) PLUS CISPLATIN/FLUOROURACIL (CIS/5FU) OR CARBOPLATIN/PACLITAXEL (CARBO/PAC) FOR 1ST-LINE TREATMENT OF RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF HEAD AND NECK (RMSCCHN)

2014 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Phase 1b Study of MEHD7945A (DULIGOTUZUMAB) Plus Cisplatin/Fluorouracil or Carboplatin/Paclitaxel for First-Line Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck

2014
Show All
- Source
- Cite
- Save
Citations (1)